+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Tardive Dyskinesia Treatment Market 2019-2023 - Product Image

Global Tardive Dyskinesia Treatment Market 2019-2023

  • ID: 4662753
  • Report
  • October 2018
  • Region: Global
  • 113 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • Merck
  • Neurocrine Biosciences
  • Novartis
  • Teva Pharmaceutical
  • MORE
About Tardive Dyskinesia

Tardive dyskinesia is the involuntary movement of face and body as a side effect of using antipsychotic drugs for the treatment of mental disorders such as schizophrenia, bipolar disorder, and other brain conditions.

The analysts forecast the Global Tardive Dyskinesia Treatment Market to grow at a CAGR of 4.44% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the tardive dyskinesia treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of tardive dyskinesia across the globe.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, tardive dyskinesia treatment market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F. Hoffmann-La Roche
  • Merck
  • Neurocrine Biosciences
  • Novartis
  • Teva Pharmaceutical
Market drivers
  • Increasing use of antipsychotic drugs across the globe
  • For a full, detailed list, view the full report
Market challenges
  • Lack of awareness
  • For a full, detailed list, view the full report
Market trends
  • Increasing R&D on VMAT2 inhibitors
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2023 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the Key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • Merck
  • Neurocrine Biosciences
  • Novartis
  • Teva Pharmaceutical
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • AUSTEDO and INGREZZA - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche
  • Merck
  • Neurocrine Biosciences
  • Novartis
  • Teva Pharmaceutical
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
PART 15: About the Author


List of Exhibits
Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global CNS therapeutics market
Exhibit 03: Market segments
Exhibit 04: Market definition - Inclusions and exclusions checklist
Exhibit 05: Market size 2018
Exhibit 06: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 07: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 08: Five forces analysis 2018
Exhibit 09: Five forces analysis 2023
Exhibit 10: Bargaining power of buyers
Exhibit 11: Bargaining power of suppliers
Exhibit 12: Threat of new entrants
Exhibit 13: Threat of substitutes
Exhibit 14: Threat of rivalry
Exhibit 15: Market condition - Five forces 2018
Exhibit 16: Product - Market share 2018-2023 (%)
Exhibit 17: Comparison by product
Exhibit 18: AUSTEDO and INGREZZA - Market size and forecast 2018-2023 ($ millions)
Exhibit 19: AUSTEDO and INGREZZA - Year-over-year growth 2019-2023 (%)
Exhibit 20: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Others - Year-over-year growth 2019-2023 (%)
Exhibit 22: Market opportunity by product
Exhibit 23: Customer landscape
Exhibit 24: Market share by geography 2018-2023 (%)
Exhibit 25: Geographic comparison
Exhibit 26: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 28: Top 3 countries in Americas
Exhibit 29: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in EMEA
Exhibit 32: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in APAC
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Molecules in late-stage development
Exhibit 38: Recent approvals by US FDA
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: F. Hoffmann-La Roche - Vendor overview
Exhibit 46: F. Hoffmann-La Roche - Business segments
Exhibit 47: F. Hoffmann-La Roche - Organizational developments
Exhibit 48: F. Hoffmann-La Roche - Segment focus
Exhibit 50: F. Hoffmann-La Roche - Key offerings
Exhibit 51: F. Hoffmann-La Roche - Key customers
Exhibit 52: Merck - Vendor overview
Exhibit 53: Merck - Business segments
Exhibit 54: Merck - Organizational developments
Exhibit 55: Merck - Segment focus
Exhibit 56: Merck – Geographic focus
Exhibit 57: Merck - Key offerings
Exhibit 58: Merck - Key customers
Exhibit 59: Neurocrine Biosciences - Vendor overview
Exhibit 60: Neurocrine Biosciences - Organizational developments
Exhibit 61: Neurocrine Biosciences - Key offerings
Exhibit 62: Neurocrine Biosciences - Key customers
Exhibit 63: Novartis - Vendor overview
Exhibit 64: Novartis - Business segments
Exhibit 65: Novartis - Organizational developments
Exhibit 66: Novartis - Segment focus
Exhibit 67: Novartis – Geographic focus
Exhibit 68: Novartis - Key offerings
Exhibit 69: Novartis - Key customers
Exhibit 70: Teva Pharmaceutical - Vendor overview
Exhibit 71: Teva Pharmaceutical - Business segments
Exhibit 72: Teva Pharmaceutical - Organizational developments
Exhibit 73: Teva Pharmaceutical - Segment focus
Exhibit 75: Teva Pharmaceutical - Key offerings
Exhibit 76: Teva Pharmaceutical - Key customer
Exhibit 77: Validation techniques employed for market sizing
Exhibit 78: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • Merck
  • Neurocrine Biosciences
  • Novartis
  • Teva Pharmaceutical
  • MORE
Global Tardive Dyskinesia Treatment Market 2019-2023

The author of the report recognizes the following companies as the key players in the global tardive dyskinesia treatment market: F. Hoffmann-La Roche, Merck, Neurocrine Biosciences, Novartis, and Teva Pharmaceutical.

Commenting on the report, an analyst from the research team said: “One trend affecting this market is the increasing R&D on VMAT2 inhibitors. Most of the established companies in the global tardive dyskinesia treatment market are focused on developing novel therapeutics by researching extensively on VMAT2 inhibitors.”

According to the report, one driver influencing this market is the driven by the increasing use of antipsychotic drugs across the globe. There has been a significant rise in the administration of antipsychotic drugs which is resulting in growing prevalence of tardive dyskinesia.

Further, the report states that one challenge affecting this market is the lack of awareness. The growth of the market is impeded by the lack of awareness about the disorder in many regions.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • F. Hoffmann-La Roche
  • Merck
  • Neurocrine Biosciences
  • Novartis
  • Teva Pharmaceutical
Note: Product cover images may vary from those shown
Adroll
adroll